AHELP

NCT02329860 📎

Regimen

Experimental
apatinib 750 mg PO daily
Control
placebo

Population

Advanced hepatocellular carcinoma refractory/intolerant to >=1 prior line of systemic chemotherapy or targeted therapy (HBV-endemic Chinese population)

Key finding

mOS 8.7 vs 6.8 mo (HR 0.785, 95% CI 0.617-0.998, p=0.048); modest but statistically significant; Chinese-only cohort; apatinib/rivoceranib = VEGFR2 TKI later used as 1L backbone in CARES-310; etiology **HBV ~82%**

Source: PMID 33971141

Timeline

    Guideline citations

    • NCCN HCC (p.73)